Researchers recently found that 5% povidone-iodine (PVP-I) used as a one-time treatment is safe and well tolerated by patients with adenoviral conjunctivitis.
A recent double-masked trial included 56 participants randomized to a one-time administration of PVP-I or preservative-free artificial tears. The team assessed safety using corneal fluorescein staining, and visual acuity (VA) and tolerability using participant-rated overall ocular discomfort.
In the PVP-I group, the study authors discovered that corneal staining increased immediately post-administration but returned to baseline levels by day one. They noted no change in VA between baseline and day one in either group. In the PVP-I group, they also found no change in participant-rated overall discomfort immediately post-administration or on day one compared with baseline.
In the artificial tear group, on the other hand, they note that participant-rated overall discomfort was lower immediately post-administration but returned to baseline levels by day one. They add that there was one adverse event in the povidone-iodine group within the first two days that was unrelated to treatment.
|Shorter E, Whiteside M, Harthan J, et al. Safety and tolerability of a one-time, in-office administration of 5% povidone-iodine in the treatment of adenoviral conjunctivitis: the Reducing Adenoviral Patient Infected Days (RAPID) study. Ocul Surf. August 8, 2019. [Epub ahead of print].|